RSU1 (Ras Suppressor Protein 1)

Its high expression was not conducive to the prognosis of patients and would also reduce the immune infiltration level of CD8+ T cells. These findings provide a preliminary theoretical basis for the research on RSU1 as a potential target for prognosis assessment and immunotherapy of CRC.

In gastrointestinal cancers, RSU1 is increased in tumor tissues, and predicts poor survival of patients. Increased RSU1 may be involved in promoting macrophage polarization, DC infiltration, and T cell exhaustion, inducing tumor immune escape and the development of tumors in GICs. We suggest that RSU1 is a promising prognostic biomarker reflecting immune infiltration level of GICs, as well as a potential therapeutic target for precision treatment through improving the immune response.

This is the first study linking RSU1L with apoptosis and provides evidence for its differential role in cell lines of different invasive potential. This indicates that RSU1L represses apoptosis in aggressive BC cells helping them evade cell death and survive.